Cargando…

A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions

The success of applications of physiologically‐based pharmacokinetic (PBPK) modeling in drug development and drug labeling has triggered regulatory agencies to demand rigorous demonstration of the predictive capability of the specific PBPK platform for a particular intended application purpose. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Frechen, Sebastian, Solodenko, Juri, Wendl, Thomas, Dallmann, André, Ince, Ibrahim, Lehr, Thorsten, Lippert, Jörg, Burghaus, Rolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213412/
https://www.ncbi.nlm.nih.gov/pubmed/33946131
http://dx.doi.org/10.1002/psp4.12636
_version_ 1783709841912496128
author Frechen, Sebastian
Solodenko, Juri
Wendl, Thomas
Dallmann, André
Ince, Ibrahim
Lehr, Thorsten
Lippert, Jörg
Burghaus, Rolf
author_facet Frechen, Sebastian
Solodenko, Juri
Wendl, Thomas
Dallmann, André
Ince, Ibrahim
Lehr, Thorsten
Lippert, Jörg
Burghaus, Rolf
author_sort Frechen, Sebastian
collection PubMed
description The success of applications of physiologically‐based pharmacokinetic (PBPK) modeling in drug development and drug labeling has triggered regulatory agencies to demand rigorous demonstration of the predictive capability of the specific PBPK platform for a particular intended application purpose. The effort needed to comply with such qualification requirements exceeds the costs for any individual PBPK application. Because changes or updates of a PBPK platform would require (re‐)qualification, a reliable and efficient generic qualification framework is needed. We describe the development and implementation of an agile and sustainable technical framework for automatic PBPK platform (re‐)qualification of PK‐Sim(®) embedded in the open source and open science GitHub landscape of Open Systems Pharmacology. The qualification approach enables the efficient assessment of all aspects relevant to the qualification of a particular purpose and provides transparency and traceability for all stakeholders. As a showcase example for the power and versatility of the qualification framework, we present the qualification of PK‐Sim(®) for the intended purpose of predicting cytochrome P450 3A4 (CYP3A4)–mediated drug–drug interactions (DDIs). Several perpetrator PBPK models featuring various degrees of CYP3A4 modulation and different types of mechanisms (competitive inhibition, mechanism‐based inactivation, and induction) were coupled with a set of PBPK models of sensitive CYP3A4 victim drugs. Simulations were compared to a comprehensive data set of 135 observations from published clinical DDI studies. The platform's overall predictive performance showed reasonable accuracy and precision (geometric mean fold error of 1.4 for both area under the plasma concentration‐time curve ratios and peak plasma concentration ratios with/without perpetrator) and suggests that PK‐Sim(®) can be applied to quantitatively assess CYP3A4‐mediated DDI in clinically untested scenarios.
format Online
Article
Text
id pubmed-8213412
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82134122021-06-28 A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions Frechen, Sebastian Solodenko, Juri Wendl, Thomas Dallmann, André Ince, Ibrahim Lehr, Thorsten Lippert, Jörg Burghaus, Rolf CPT Pharmacometrics Syst Pharmacol Research The success of applications of physiologically‐based pharmacokinetic (PBPK) modeling in drug development and drug labeling has triggered regulatory agencies to demand rigorous demonstration of the predictive capability of the specific PBPK platform for a particular intended application purpose. The effort needed to comply with such qualification requirements exceeds the costs for any individual PBPK application. Because changes or updates of a PBPK platform would require (re‐)qualification, a reliable and efficient generic qualification framework is needed. We describe the development and implementation of an agile and sustainable technical framework for automatic PBPK platform (re‐)qualification of PK‐Sim(®) embedded in the open source and open science GitHub landscape of Open Systems Pharmacology. The qualification approach enables the efficient assessment of all aspects relevant to the qualification of a particular purpose and provides transparency and traceability for all stakeholders. As a showcase example for the power and versatility of the qualification framework, we present the qualification of PK‐Sim(®) for the intended purpose of predicting cytochrome P450 3A4 (CYP3A4)–mediated drug–drug interactions (DDIs). Several perpetrator PBPK models featuring various degrees of CYP3A4 modulation and different types of mechanisms (competitive inhibition, mechanism‐based inactivation, and induction) were coupled with a set of PBPK models of sensitive CYP3A4 victim drugs. Simulations were compared to a comprehensive data set of 135 observations from published clinical DDI studies. The platform's overall predictive performance showed reasonable accuracy and precision (geometric mean fold error of 1.4 for both area under the plasma concentration‐time curve ratios and peak plasma concentration ratios with/without perpetrator) and suggests that PK‐Sim(®) can be applied to quantitatively assess CYP3A4‐mediated DDI in clinically untested scenarios. John Wiley and Sons Inc. 2021-05-24 2021-06 /pmc/articles/PMC8213412/ /pubmed/33946131 http://dx.doi.org/10.1002/psp4.12636 Text en © 2021 Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Frechen, Sebastian
Solodenko, Juri
Wendl, Thomas
Dallmann, André
Ince, Ibrahim
Lehr, Thorsten
Lippert, Jörg
Burghaus, Rolf
A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions
title A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions
title_full A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions
title_fullStr A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions
title_full_unstemmed A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions
title_short A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions
title_sort generic framework for the physiologically‐based pharmacokinetic platform qualification of pk‐sim and its application to predicting cytochrome p450 3a4–mediated drug–drug interactions
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213412/
https://www.ncbi.nlm.nih.gov/pubmed/33946131
http://dx.doi.org/10.1002/psp4.12636
work_keys_str_mv AT frechensebastian agenericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT solodenkojuri agenericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT wendlthomas agenericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT dallmannandre agenericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT inceibrahim agenericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT lehrthorsten agenericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT lippertjorg agenericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT burghausrolf agenericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT frechensebastian genericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT solodenkojuri genericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT wendlthomas genericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT dallmannandre genericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT inceibrahim genericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT lehrthorsten genericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT lippertjorg genericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions
AT burghausrolf genericframeworkforthephysiologicallybasedpharmacokineticplatformqualificationofpksimanditsapplicationtopredictingcytochromep4503a4mediateddrugdruginteractions